Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
185 Results for "
Exatecan
" in MedChemExpress (MCE) Product Catalog:
Products (185)
185 Results for "Exatecan" in MCE Product Catalog:
Cat. No.: HY-174279
CAS No.: 3052836-65-1
Target:
Research Areas:
MCC-AAQ-Exa is a drug-linker conjugates for ADC, obtained by condensing the linker with Exatecan (HY-13631) and can be used to prepare antibody-drug conjugates (ADCs). MCC is an ADC linker containing a maleimide fragment .
Cat. No.: HY-49412
CAS No.: 2866301-96-2
Target:
Research Areas:
Fmoc-Gly-Gly-Phe-Gly-NH-CH2-O-CO-CH3 (compound DC-13-C) is an intermediate in the synthesis of Exatecan (HY-13631) derivatives .
Cat. No.: HY-168489
CAS No.: 3039487-10-7
Target:
Research Areas:
OBI-992 drug-linker is a drug-linker conjugate composed of the TOP I inhibitor Exatecan (HY-13631) and a linker. OBI-992 drug-linker can be used for the synthesis of the ADC OBI-992 .
Cat. No.: HY-164836
Research Areas:
Deruxtecan-Eribulin is a Drug-Linker Conjugates for ADC, which is composed of a linker and a toxic molecule Exatecan (HY-13631) (DNA topoisomerase I inhibitor) and Eribulin (HY-13442) (Microtubule inhibitor). Deruxtecan-Eribulin can be used for ADC synthesis.
Cat. No.: HY-183558
CAS No.: 3107874-31-4
Research Areas:
AV-DL055 is a conjugate of the toxin molecule Exatecan (HY-13631) and the linker AV-L03 (HY-183678). AV-DL055 can be used to construct ADCs, such as T-DL055 .
Cat. No.: HY-177711
CAS No.: 2938864-88-9
Synonyms: SHR-A1921
Target:
Research Areas:
Tizetatug rezetecan (SHR-A1921) is an Antibody-drug Conjugate (ADC) composed of antibody Tizetatug (HY-P991032) and MC-Gly-Gly-Phe-Gly-(R)-Cyclopropane-Exatecan (HY-148668). Tizetatug rezetecan can be used for the research of cancer .
Cat. No.: HY-177495
CAS No.: 3094583-35-1
Research Areas:
LD-38 is a drug-linker conjugate for ADC. LD-38 consists of a topoisomerase 1 inhibitor (Exatecan) (HY-13631) and a highly hydrophilic stable and cleavable linker. LD-38 can be used for synthesis of ADCs, such as KA-3123-LD38 .
Cat. No.: HY-W250541
CAS No.: 2414254-47-8
Target:
Research Areas:
Fmoc-Gly-NH-CH2-O-Cyclopropane-CH2COOH is an intermediate in the synthesis of ADC linker.The linker composed of Benzyl 2-cyclopropyl-2-hydroxyacetate can be coupled to Exatecan (HY-13631) and combined with antibodies (such as antibody hu2F7) .
Cat. No.: HY-177434
CAS No.: 2873366-83-5
Synonyms: Precem-TcT; M 9140
Cat. No.: HY-184739
CAS No.: 3120799-14-3
Target:
Research Areas:
SMP-70067-L (DL10) is a conjugate of a toxic molecule and a linker, in which the toxin moiety is Exatecan (HY-13631) and the linker moiety is SMP-93566-4-Leu-Cit-PAB-Glu (Ac) (HY-184740). SMP-70067-L can be used to synthesize the ADC SMP-70067-X .
Cat. No.: HY-186185
CAS No.: 3091519-75-1
Research Areas:
OSu-Val-Cit-PAB-Exa (compound D) is a cleavable linker-payload conjugate (usable for ADC synthesis). OSu-Val-Cit-PAB-Exa bears an N-terminal N-hydroxysuccinimide (OSu) ester group, and comprises Val-Cit, p-aminobenzyl alcohol (PAB) and Exatecan (HY-13631). OSu-Val-Cit-PAB-Exa serves as a payload-linker intermediate for polypeptide conjugation .
Cat. No.: HY-173639
Research Areas:
AZD0516 is an antibody-drug conjugate (ADC) targeting STEAP2. It is formed by conjugating an anti-STEAP2 monoclonal antibody (mAb) via interchain cysteines to a maleimide-reactive, β-glucuronidase-cleavable linker (HY-173635) and the topoisomerase 1 inhibitor Exatecan (HY-13631). AZD0516 is applicable to the research of metastatic castration-resistant prostate cancer .
Cat. No.: HY-184561
CAS No.: 3128805-51-3
Target:
Research Areas:
L05-EXd is a toxin-linker conjugate, in which the toxin component is Exatecan (HY-13631). L05-EXd can be conjugated with Polatuzumab (HY-P99042) to form the ADC molecule Polatuzumab-L05-EXd. L05-EXd is applicable to research related to small cell lung cancer and non-small cell lung cancer .
Cat. No.: HY-158109
Purity: 99.39%
Cat. No.: HY-184906
Target:
Research Areas:
Mal-PEG4-Val-Ala-Ph-2,2-dimethylpropanoic acid is a maleimide-functionalized PEG4-Val-Ala dipeptide linker bearing a trimethyl-locked adapter for exatecan conjugation, which enables thiol conjugation via the maleimide group and facilitates payload release. Mal-PEG4-Val-Ala-Ph-2,2-dimethylpropanoic acid is used in cancer research .
Cat. No.: HY-176415
CAS No.: 3025787-83-8
Target:
Research Areas:
Cys-MC-GGFG-Dxd is a cysteine-modified, cleavable ADC drug-linker conjugate. Cys-MC-GGFG-Dxd consists of a maleimidocaproyl-glycine-glycine-L-phenylalanine-glycine (MC-GGFG) linker and an Exatecan (HY-13631) derivative (DXd) (HY-13631D) payload. Cys-MC-GGFG-Dxd can be further conjugated to anti-HER2 IgG1κ antibody for the synthesis of antibody-drug conjugates (ADC), such as the breast cancer-targeting ADC compound Fam-trastuzumab deruxtecan-nxki (Enhertu) .
Cat. No.: HY-181679
Target:
Research Areas:
TML-2Cl is a dichloro-modified trimethyl lock adapter for antibody-drug conjugates and payload releaser.TML-2Cl undergoes 1,6-elimination followed by rapid self-cyclization to facilitate release of the payload Exatecan after cathepsin B cleavage of the associated linker.TML-2Cl exhibits high stability when conjugated to a drug and high intrinsic hydrophobicity.TML-2Cl can be used for the research of gastric carcinoma .
Cat. No.: HY-188015
CAS No.: 3086791-85-4
Target:
Research Areas:
DBCO-PEG4-GGFG-Triptolide is a triptolide-based antibody-drug conjugate (ADC) payload, consisting of a DBCO click chemistry reactive group, a PEG4 linker, a cathepsin-cleavable GGFG peptide segment, and triptolide. DBCO-PEG4-GGFG-Triptolide binds to antibodies via glycosylation conjugation, releases active triptolide intracellularly to exert cytotoxic effects, and is commonly used in combination with camptothecin-class toxins (Exatecan (HY-13631) / DXd (HY-13631D)) for the preparation of dual-toxin ADCs .
Cat. No.: HY-184905
Target:
Research Areas:
W1507 is an NH2-TML-based linker-payload conjugate, in which the payload is Exatecan (HY-13631) and the linker is Mal-PEG4-Val-Ala-Ph-2,2-dimethylpropanoic acid (HY-184906). W1507 can be conjugated with Trastuzumab (HY-P9907) to synthesize the ADC Her2-W1507. Her2-W1507 exhibits in vivo anti-tumor activity. W1507 can be used for the research of gastric cancer, ovarian adenocarcinoma and Her2-amplified breast cancer .
Cat. No.: HY-P990940
CAS No.: 2883118-92-9
Synonyms: MBE-748; M-9140 Antibody; MBE-2882 Antibody
Target:
Research Areas:
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
